Screener
iRadimed IRMD Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by iRadimed in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: iRadimed’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029325
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Allowance for credit losses | 40 | (15) |
| Provision for excess and obsolete inventory | 15 | (38) |
| Depreciation & amortization | 455 | 194 |
| Stock-based compensation | 684 | 826 |
| Deferred income taxes, net | (137) | 130 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 212 | (2,135) |
| Inventory | (534) | (120) |
Item 1. Condensed Financial Statements
FAQ
- What is iRadimed's stock-based comp?
- iRadimed (IRMD) reported stock-based comp of $684K in Q1 2026.
- How has iRadimed's stock-based comp changed year-over-year?
- iRadimed's stock-based comp decreased by 17.2% year-over-year, from $826K to $684K.
- What is the long-term trend for iRadimed's stock-based comp?
- Over 4 years (2021 to 2025), iRadimed's stock-based comp has grown at a 17.8% compound annual growth rate (CAGR), from $1.52M to $2.92M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about iRadimed's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude